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Abstract
In diabetic patients with acute kidney injury (AKI), kidney biopsy often reveals non-diabetic
kidney pathology. This case describes a patient with known Type 1 diabetes who presented with
AKI, nephrotic syndrome and haematuria. Combination pathology of seronegative anti-glomeru-
lar basement membrane antibody-mediated glomerulonephritis (anti-GBM GN), membranous
nephropathy (MN) and diabetic nephropathy (DN) was demonstrated. Strong linear GBM IgG-
staining on biopsy with crescentic GN and clinical AKI led to a diagnosis of anti-GBM GN, although
serum antibodies were not detectable. Features of DN, Kimmelstiel–Wilson nodules and albumin
staining were also present, along with features of MN, such as subepithelial deposits on electron
microscopy. Despite treatment with immunosuppression and plasmapheresis, there was no re-
covery of kidney function. Coexisting anti-GBM GN and MN is well recognized, but the concurrent
diagnosis with DN has not been described.
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Background
Non-diabetic kidney disease in patients with diabetes is
identiﬁed in biopsy-based studies with frequencies ranging
10–60% [1–3]. Indications for kidney biopsy in patients
with diabetes are the presence of features atypical for dia-
betic nephropathy (DN); glomerular haematuria, acute
kidney deterioration or severe proteinuria [2, 3]. Membra-
nous nephropathy (MN) and IgA nephropathy (IgAN),
superimposed on DN, are most prevalent in communities
with a relatively high incident of disease, respectively [1, 2].
MN alongside of DN can present with severe proteinuria
and progress quickly to dialysis-dependent end-stage
kidney disease (ESKD) [4]. Concomitant anti-glomerular
basement membrane (GBM) glomerulonephritis (GN) and
DN is rare, with poor kidney outcomes reported [5–8]. The
simultaneous or sequential occurrence of anti-GBM GN and
MN is well recognized [9]. However, this is the ﬁrst report of
concurrent seronegative anti-GBM GN, MN and DN.
Case report
A 22-year-old Caucasian male with Type 1 diabetes
mellitus (T1DM), presented with acute kidney injury (AKI),
serum creatinine (SCr) 387 μmol/L and nephrotic
syndrome (timed urinary protein excretion 14 g/day,
serum albumin 23 g/L (35–50 g/L), underwent a diagnos-
tic kidney biopsy. Clinical assessment 1 year prior indi-
cated minimal proteinuria (albumin-to-creatinine ratio
1.5 mg/mmol) and normal kidney function (eGFR [10]
>90 mL/min/1.73 m2) at that time. Antineutrophil cyto-
plasmic, extractable nuclear antigen (ENA) and anti-GBM
antibodies were undetected. Urine studies showed
protein-to-creatinine ratio 1.133 g/mmol, dysmorphic
erythrocytes (>1000 × 106/L) and lipiduria.
T1DM was diagnosed at age 2 and insulin therapy de-
livered via insulin pump. Glycosylated haemoglobin
(HbA1c) at presentation was 7.2%. The patient weighed
100 kg and had smoked 10 cigarettes per day for the
past 7 years. There was no history of retinopathy or hy-
pertension, illicit or non-steroidal anti-inﬂammatory drug
use or alcohol dependence. He had been commenced on
frusemide and irbesartan/hydrochlorothiazide 3 weeks
earlier to treat oedema.
The kidney biopsy demonstrated a focal segmental
necrotizing GN with cellular and ﬁbrocellular crescents
involving 29 of 40 glomeruli; another 6 glomeruli were
sclerosed. Glomeruli had moderate nodular mesangial
expansion and hypercellularity with several showing
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Kimmelstiel–Wilson nodules. Numerous tubular red blood
cell casts were present. There was moderate interstitial
ﬁbrosis and tubular atrophy with a patchy interstitial
mixed chronic inﬂammatory cell inﬁltrate (see Figures 1A
and B and 2A and B). Immunoﬂuorescence showed
strong linear GBM staining for IgG. Weaker anti-albumin
staining localized in a linear fashion to the GBM,
Bowman’s capsule (BC) and tubular basement membrane
(TBM) staining (Figure 3A and B). Under oil immersion
(×1000 magniﬁcation), a dual pattern of linear and gran-
ular glomerular peripheral capillary wall staining was
seen. This was conﬁrmed by confocal microscopy
(Figure 4A–C). Electron microscopy showed Stage 1 MN
with small subepithelial electron-dense ‘immune-type’
deposits with early GBM spike formation (Figure 5A and B).
The overall diagnosis was that of anti-GBM GN and
Stage 1 MN superimposed on Class III DN with Kimmel-
stiel–Wilson lesions.
The simultaneous diagnosis of seronegative anti-GBM
GN, MN and DN was consistent with clinical presentation
of proteinuria, haematuria and AKI, although unex-
pected, as anti-GBM antibody serology was negative
(Orgentec, Mainz, Germany). A more sensitive biosensor
assay was unavailable. The patient’s human leucocyte
antigens (HLA) were: A1, 24; B8, 39; DR4, 16. Screening
for serum anti-secretory phospholipase A2 receptor
(PLA2R) antibodies was not detected using an indirect
immunoﬂuorescence test (Euroimmun AG, Lubeck,
Germany) [11]. In addition, PLA2R was not detected
by immunoﬂuorescence in the parafﬁn-embedded
kidney biopsy using anti-rabbit PLA2R antibody (Atlas
Antibodies).
Treatment included corticosteroids (3× intravenous
methylprednisolone 1 g/day then 75 mg/day oral predniso-
lone), oral cyclophosphamide (2 mg/kg/day) after fertility
protection measures and 10 alternate-daily plasmapher-
esis treatments (3 L volume exchanges, replacement
albumin 4%). He was discharged with mildly improved
stable kidney function, with SCr 253 μmol/L.
Fig. 1. (A) The glomerulus shows nodular mesangial expansion and
hypercellularity. (B) This glomerulus shows segmental necrosis (arrow)
and large cellular crescent (asterisk). Haematoxylin and eosin stain.
Original magniﬁcation ×400.
Fig. 2. (A) This glomerulus shows a Kimmelstiel–Wilson nodule (arrow).
(B) This glomerulus shows a large cellular crescent (arrows). Periodic acid
Silver stain. Original magniﬁcation ×400.
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One week later, he developed small-volume haemopty-
sis that settled with oral antibiotics, cessation of smoking
and cyclophosphamide reduction (1.5 mg/kg/day). Signiﬁ-
cant oedema persisted despite maximal oral diuretic
therapy. Five weeks later, he developed neutropaenia ne-
cessitating withdrawal of cyclophosphamide. Prednisolone
60 mg/day was continued in light of further deterioration
in kidney function, with SCr 383 μmol/L and worsening
proteinuria at 19 g/day.
Another nine alternate-daily plasmapheresis treat-
ments were initiated once neutropaenia resolved, at-
tempting to salvage kidney function. The renal function
remained severely impaired and proteinuria worsened to
21 g/day. His clinical course was complicated by H. Zoster
reactivation (T7 dermatome) that resolved with valaciclo-
vir treatment. Anti-GBM serology remained undetectable
throughout.
Progressive renal disease and inability to monitor
disease activity serologically led to a repeat kidney biopsy,
which showed segmental sclerotic lesions and ﬁbrous
crescents in 13 of 22 glomeruli and another 3 glomeruli
sclerosed. No segmental necrotizing lesions or cellular
crescents were seen. Immunoﬂuorescence showed a
strong dual pattern of staining for IgG as described in the
ﬁrst biopsy (not illustrated). The overall diagnosis of the
subsequent biopsy was inactive anti-GBM GN and MN
superimposed on DN. Persistent strong linear GBM staining
for IgG despite lack of active lesions in this biopsy.
The patient commenced maintenance haemodialysis
14 weeks after initial presentation when refractory ﬂuid
overload ensued, coupled with no renal recovery. Immu-
nosuppression was discontinued. Currently, 5 months
after presentation, he is training for home haemodialysis
and suitability for combined kidney–pancreas transplant
is being assessed.
Discussion
This is an unusual report of the simultaneous diagnosis
in a kidney biopsy of seronegative anti-GBM GN, MN and
DN. Kidney biopsy was undertaken in this patient with
longstanding diabetes and clinical renal parameters
not typical of DN. He presented with nephrotic range pro-
teinuria, an active urinary sediment and AKI. Pulmonary
involvement from anti-GBM disease was uncertain, as
haemoptysis was minimal, settled with antibiotics and
occurred in the context of smoking and recent immuno-
suppression. Absence of serum anti-GBM antibodies
made serological assessment of disease activity difﬁcult.
Anti-GBM kidney disease, characteristically a rapidly
progressive crescentic GN associated with pulmonary
haemorrhage and circulating anti-GBM antibodies
directed against the NC1 domain of type IV collagen α3
chain (α3(IV)NC1) [12], is commonly diagnosed through a
Fig. 3. (A) Direct immunoﬂuorescence shows strong linear GBM staining
for IgG. BC and tubular BM are negative. (B) In contrast, albumin shows
strong staining of GBM, BC and TBM. Original magniﬁcation ×400.
Fig. 4. (A–C) Direct immunoﬂuorescence at a higher magniﬁcation shows
a dual pattern of IgG immunoﬂuorescence with linear GBM staining
together with granular staining on the outside or urinary space aspect of
the GBM (arrows). Images (B) and (C) were acquired on a Nikon A1Rsi
confocal microscope with a Z-slice of 0.6 μm.
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combination of clinical, histological and serological ﬁnd-
ings [13]. Seronegative anti-GBM disease occurs in ∼2–
3% of cases, where antibodies not detected by ELISA
methods are found with other biosensor techniques [14].
Jia et al. [15] suggest that circulating anti-GBM antibodies
undetectable by ELISA may recognize cryptic and highly
conformation-dependent epitopes restricted on α3(IV)
NC1. They used indirect immunoﬂuorescence for antibody
detection. However, the gold standard for anti-GBM GN
diagnosis is strong linear GBM histological staining for IgG.
Occurrence of crescentic GN with DN is uncommon,
with ﬁve previous reports of anti-GBM GN superimposed
on DN [5–8], and only one subject recovered kidney func-
tion [6]. Three patients had SCr >880 μmol/L prior to
treatment initiation. Poor prognostic factors for kidney re-
covery described in anti-GBM GN include oligoanuria, SCr
>600 μmol/L, high serum anti-GBM antibodies (ELISA)
levels and a high percentage of crescents on biopsy [16].
In biopsy-based studies, MN is a relatively common
non-diabetic kidney pathology in diabetic populations
[1, 2]. Though, severe proteinuria as biopsy indication
suggests selection bias, as an autopsy study investigating
kidney pathology in diabetes demonstrated no MN cases
and only one IgAN in 210 subjects [17]. Outcomes in
those with combined MN and DN are poor, both contri-
buting to worsening proteinuria and acceleration of
kidney injury [18].
Conversely, associations between MN and anti-GBM GN
are well recognized, and were ﬁrst described in 1974 [19].
Two recent reviews identiﬁed ∼30 cases, sequential oc-
currence in one-third (either anti-GBM GN following MN
or vice versa), and simultaneous diagnosis in the remain-
der [9, 20]. Reported outcomes varied with kidney recov-
ery in one-third, progression to ESKD in the majority and
death in four patients. Some have speculated that initial
alteration in basement membrane permeability allows
further disruption leading to heightened immune system
exposure and development of additional disease [9, 21].
Seronegative anti-GBM GN and MN have not been re-
ported together, although seronegativity itself is rare.
All three diseases, in part at least, implicate autoimmu-
nity. Anti-GBM disease is one of the few human auto-
immune diseases where the autoantigen is known [22]
with multiple HLA-positive associations, namely HLA-
DR15 and HLA-DR4 [23, 24]. HLA typing in our patient
was positive for HLA-DR4 and -DR16 but negative for
-DR15. More recently, primary MN has been linked with
the HLA-DQA1 allele on chromosome 6p21 [25], and
PLA2R identiﬁed as a major autoantigen [26]. Circulating
autoantibodies against M-type PLA2R in the podocyte are
present in 70% of idiopathic MN patients [26]. Serum
PLA2R antibody was negative in this patient and PLA2R
was not detected in the glomeruli on biopsy. Hence, the
features do not support diagnosis of idiopathic MN.
Rather secondary MN subsequent to GBM/podocyte injury
caused by anti-GBM GN and/or DN is postulated. T1DM,
long considered a chronic autoimmune disease, results
from anti-islet autoimmunity developing in genetically
susceptible individuals [26], where major susceptibility
loci map to HLA-DRB1 and HLA-DQB1, also located on
chromosome 6p21 [27]. Immunological tolerance mech-
anisms prevent these diseases in healthy individuals
and occurrence of all three in our patient suggests such
tolerance may have broken down.
Presence of DN can complicate kidney biopsy interpret-
ation of other pathology. In diabetes, the biopsy shows
weak to moderate linear staining of GBM, BC and TBM for
IgG and albumin [28]. However, in this case, there was
very strong linear GBM staining for IgG with negligible
staining in BC and TBM, a pattern diagnostic of anti-GBM
GN. In contrast, albumin showed diffuse moderate stain-
ing of GBM, BC and TBM (illustrated in Figure 3A).
With triple pathology, kidney recovery seemed unlikely
despite reasonable prognostic markers at presentation,
SCr <600 μmol/L and urine output >2 L/day. Progression
of disease despite aggressive immunosuppression
prompted repeat kidney biopsy to guide treatment. Sub-
sequent complications, neutropaenia and opportunistic
infection, in the setting of worsening histology with less
overall activity, resulted in immunosuppression cessation
and dialysis commencement, with a view to future com-
bined kidney–pancreas transplantation.
The kidney biopsy in glomerular disease is invaluable,
providing diagnosis and important disease information
whilst aiding management decisions [13]. Despite ad-
vances with serological testing [13], this case continues
to illustrate the importance of the biopsy. Such as in this
instance, kidney biopsies of patients with diabetes, par-
ticularly those with clinical features not typical of DN,
may reveal other potentially treatable kidney pathology.
Conﬂict of interest statement. None declared.
Fig. 5. (A and B) Transmission electron microscopy shows GBM thickening
with small subepithelial electron-dense deposits (arrows) with early GBM
spike formation (double arrows). Original magniﬁcation ×10 000.
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